Bayer, J&J land top 10 spots in brand power ranking

Tenet Partners is out with its ninth annual evaluation of the most powerful brands, and a pair of pharmas locked up top spots on the list.

Bayer finished at No. 3 for the second year in a row, while Johnson & Johnson finished in eighth place. But J&J actually dropped two positions from last year's No. 6 performance, making it the biggest decliner among the top 10 brands.

The drugmakers are in well-known company: Coca-Cola finished first for the ninth time in the study--which includes interviews with 10,000 global business executives--followed by Hershey at No. 2.

As Tenet notes, while a brand is considered an intangible asset, it is one of the most important assets a company owns. Intangible assets in general make up about 84% of the total value of S&P 500 companies, according to 2015 research by Ocean Toma.

And Bayer is on the up-and-up. It gained in favorability, a measurement of positive brand perception, in Tenet’s 2016 review after dropping in 2015.

While J&J did lose ground in brand power this year, it also finished at No. 6 in Tenet’s absolute brand value calculations. “… In our view, BrandPower is a measure of brand strength, based on successful brand management, and independent of brand value. By contrast, brand valuation is the output of a time-tested statistical model, measuring the impact of a company’s brand in the context of its financial performance," Tenet wrote in its report.

- read the news release

Related Articles:
Brand matters: Interbrand's best in pharma ranks Pfizer, Roche and Merck at top
Pfizer and Valeant jump in annual brand analysis, but most other pharmas drop
They're no Coca-Cola, but top biopharma brands Pfizer, Biogen and Merck still worth billions
Bayer, GSK, Novo and Roche rank in top 10 for online comms

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.